Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer

21 Jun 2019

Abstract excerpt

Abstract Immune checkpoint blockade ( ICB ) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer ( NSCLC ), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC patients treated by ICB ( CTLA ‐4/ PD ‐1). High tumor mutation burden ( TMB ) and neoantigen burden...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31222843
DOI: 10.1111/cas.14113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancerPMID 31222843Read ↗

APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read ↗

Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.Semantic proximity Read ↗

APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinomaSemantic proximity Read ↗

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.Semantic proximity Read ↗

Association Between Tumor Mutation Burden (TMB) and immune microenvironment in lung squamous cell carcinomaSemantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.